Ironwood Pharmaceuticals, Inc.
NASDAQIronwood Pharmaceuticals woke up Wednesday with its most significant piece of positive news in months — an FDA approval expanding LINZESS (linaclotide) to pediatric patients aged two and older for functional constipation. The story on IRWD this week is therefore less about technical positioning and more about whether a meaningful label expansion can shift a narrative…
Snapshot as of 27 May 2026
Ironwood Pharmaceuticals woke up Wednesday with its most significant piece of positive news in months — an FDA approval expanding LINZESS (linaclotide) to pediatric patients aged two and older for functional…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IRWD — free to start on ORTEX.
Sign up for free →Open IRWD on ORTEX